Abstract No. 576 Orthotopic Ovarian Cancer: Molecular Imaging-Monitored Radiofrequency Hyperthermia-Enhanced Intratumoral Herpes Simplex Virus-Thymidine Kinase (HSV-TK) Gene Therapy
Y. Li,X. Yang,F. Zhang,S. Zhao,G. Jin,L. Zhao,P. Li,Y. Zhou
DOI: https://doi.org/10.1016/j.jvir.2018.01.621
IF: 3.682
2018-01-01
Journal of Vascular and Interventional Radiology
Abstract:To validate the feasibility of using imaging-guided RF hyperthermia (RFH) to enhance intratumorl HSV-TK/Ganciclovir (GCV) suicide gene therapy of ovarian cancers, monitored by optical and ultrasound imaging. Human ovarian cancer cells (SK-OV-3) labeled with luciferase/lentivirus for in vitro confirmation and rats with the same luciferase-positive orthotopic ovarian cancers for in vivo validation were divided into four groups with different treatments: i) combination treatment with intratumoral HSV-TK/GCV-mediated gene therapy plus RFH; ii) gene therapy alone; iii) RFH alone; iv) phosphate buffered saline (PBS). MTS assay and confocal microscopy were used to evaluate the cell viability. Bioluminescence optical and ultrasound imagings were used to monitor the changes of tumor size and bioluminescence signal intensities at different time points (days 0, 7 and 14 posttreatment). The imaging findings were correlated with subsequent pathology confirmation. MTS assay demonstrated the lowest cell proliferation in the group with combination therapy, compared with three control treatments (41.0 ± 6.1% vs 47.8 ± 1.5% vs 97.3 ± 8.5% vs 100%, p<0.01), as corresponded to the smallest number of survived cells by confocal microscopy and the lowest bioluminescence signal by optical imaging. Ultrasound imaging showed the smallest tumor volume with combination therapy, compared with the other three control treatments (0.23 ± 0.19 vs 1.26 ± 0.21 vs 5.43 ± 0.33 vs 6.74 ± 0.36, p<0.05). Bioluminescent optical imaging demonstrated a significantly decreased bioluminescence signal intensity in combination therapy, compared with the other three treatments (0.35 ± 0.12 vs 1.26 ± 0.10 vs 3.43 ± 0.27 vs 3.90 ± 0.12, p<0.05). Both imaging findings were confirmed by pathology, demonstrated as the significantly increased apoptotic cells in the combination therapy group. We have successfully established the "proof-of-principle" of using image-guided intratumoral RFH to enhance HSV-TK/GCV gene therapy of rat ovarian cancers, which may provide a new opportunity for effectively managing ovarian cancers by simultaneous integration of radiofrequency technology, interventional oncology, and direct gene therapy.